Comparison between dupilumab and oral Janus kinase inhibitors in the treatment of prurigo nodularis with or without atopic dermatitis in a tertiary care center in Singapore
Main Authors: | Yik Weng Yew, MBBS, MPH, PhD, Pei Ming Yeo, MBBS, MRCP |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2023-12-01
|
Series: | JAAD International |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2666328723000949 |
Similar Items
-
Outcomes of systemic Janus kinase inhibitors following prior dupilumab use for atopic dermatitis: An evidence-based review
by: Siddhartha Sood, HBSc, et al.
Published: (2024-09-01) -
Severe cutaneous reaction with initiation of dupilumab for atopic dermatitis and prurigo nodularis: An unusual adverse effect
by: Leore Lavin, MSc, et al.
Published: (2024-07-01) -
Baricitinib for atopic dermatitis patients who responded inadequately to dupilumab treatment: First daily practice results
by: Linde deWijs, et al.
Published: (2022-12-01) -
Case report: Sequential therapy with dupilumab and baricitinib for severe alopecia areata with atopic dermatitis in children
by: Huijuan Fang, et al.
Published: (2024-06-01) -
Immediate exacerbation of atopic dermatitis after switching from upadacitinib to dupilumab: A report of two cases
by: Makoto Ito, et al.
Published: (2023-10-01)